Showing posts with label Genetics. Show all posts
Showing posts with label Genetics. Show all posts

Tuesday, August 10, 2010

New DNA test could allow earlier detection of colon cancer

Moral of the story: This is apparently a perfect test- catches all cancer and is never wrong (super rare) and this just increases the motivation you should have for getting your colonoscopy.  prevention prevention prevention

Source: AMA Morning Rounds 8/10/2010

The New York Times (8/10, D1, Wade) reports on the front of its Science Times section, "A new generation of DNA tests for colon cancer seems likely to improve the detection both of cancers and of the precancerous polyps that precede them." The Times adds that "Exact Sciences, a company based in Madison, Wis., is developing a colon cancer test based on highly methylated DNA," and "its researchers reported last month that by testing for methylated DNA at four markers, pieces of DNA drawn from specific genes, they could detect colon tumors and polyps, distinguishing them from normal tissue with 100 percent sensitivity and with no false positives."

Thursday, May 27, 2010

Physical activity or medical treatment

Moral of the story: Which do we target in health campaigns? Why not both?

Source: BMJ

(1) What's more important in the obesity battle – physical activity or medical treatment?
(Head to Head: Should health policy focus on physical activity rather than obesity?)
Yes: http://www.bmj.com/cgi/content/extract/340/may25_1/c2603 No: http://www.bmj.com/cgi/content/extract/340/may25_1/c2602
Experts disagree on bmj.com today about the best way to tackle the obesity crisis. While Professor Louise Baur and colleagues from the Children's Hospital at Westmead and the University of Sydney in Australia acknowledge that "physical inactivity is a major contributor to the global burden of disease," they says that it would be wrong to only focus on this and ignore the problem of obesity.
Baur and colleagues argue that physical inactivity is just one marker and that there is substantial evidence that unhealthy diets low in fibre and high in sugar and large portion size are also responsible for obesity and the diseases associated with it.
However, Dr Richard Weiler, a specialist registrar in sport and exercise medicine at Imperial College Healthcare NHS Trust and general practitioner, and colleagues believe that inadequate cardio-respiratory fitness causes disease more than excess body fat, waist size and body mass index.
Weiler and colleagues maintain that "physical inactivity is one of the greatest health threats facing developed nations today" and they are concerned that 95% of the populations in England and the United States do not meet the recommended guidelines of doing 30 minutes moderate to vigorous physical activity on at least five days a week or equivalent.
They say this is alarming given that physical inactivity rather than obesity per se is an actual cause for many illnesses including obesity, heart disease, type 2 diabetes, mental health problems, high blood pressure and dementia.
Spending huge amounts on treating obesity is not the right way forward, they argue. Weight loss drugs and surgery are risky and the long-term benefits are limited and they certainly do not have the associated health benefits linked to physical activity. They conclude that it is time for health policy and healthcare professionals to focus on fighting physical inactivity, a "chronic disease that has an adult population prevalence of 95%."
Professor Baur, on the other hand, believes that "on its own, improving physical activity will have little impact on reducing overall levels of already established obesity."
She believes that obese people need access to high quality treatment provided by well-trained professionals to deal with their weight and any linked health problems.
In conclusion, Professor Baur and colleagues advocate tackling obesity with a range of strategies, for example, increasing physical activity, improving diet and lifestyles. They say urban planning should be developed to encourage people to use their car less and cycle more and public transport should be made more accessible and affordable.
Contacts:
Louise Baur, The Children's Hospital at Westmead, Sydney, NSW, Australia
Email: louiseb3@chw.edu.au Richard Weiler, Specialist Registrar in Sport and Exercise Medicine, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK and General Practitioner, Hertfordshire Email: c/- cassie.zachariou@imperial.nhs.uk

Sunday, November 29, 2009

New law bans genetic discrimination.

Moral of the story: Genetic counseling needs to change to reflect the new privacy patients have in term of their genetic composition.

Source: AMA Morning Rounds 11/23/09

New law bans genetic discrimination.

The Los Angeles Times (11/22, Markman) reported that the Genetic Information Nondiscrimination Act, which has been called "the most sweeping federal anti-discrimination law in nearly 20 years," went into effect over the weekend. The law prohibits employers "from hiring, firing or determining promotions based on genetic makeup," and also forbids health insurers from using genetics as a basis for denying coverage or setting insurance rates. The law comes despite a number of concerns from insurers and the National Federation of Independent Business, who expressed concerns that employers could be held liable for having genetic information in their files.

In an editorial, the New York Times (11/22, WK9) opined that the law "is an important step in protecting people who have inherited a predisposition to disease," and "removes a significant obstacle to genetic testing." They note the objections made by insurance companies and business groups, and say that the law was passed regardless "because lawmakers rightly saw that fairness and public policy arguments demanded a ban on discriminating against people for genetic traits they can do nothing about."

Wednesday, May 13, 2009

Cancer Patients Challenge the Patenting of a Gene

Moral of the story: Patents on genes are creating controversy and in the name of free speech and medical necessity need to be restricted. They are creating undue burden for patients because of the lack of market forces preventing innovating and driving up costs. As the article states, my genes can no more ethically be patented than my left arm or my brain. The laws need to change and reflect this reality. At the same time, genetically modified foods need to be revisited as the ethics of genetic patents are reviewed. It may be time to stop bowing to argibusiness and start fighting for every American.

http://www.nytimes.com/2009/05/13/health/13patent.html?em

Cancer Patients Challenge the Patenting of a Gene

Published: May 12, 2009

When Genae Girard received a diagnosis of breast cancer in 2006, she knew she would be facing medical challenges and high expenses. But she did not expect to run into patent problems.

Benjamin Sklar for The New York Times

Genae Girard, 39, is suing Myriad Genetics and the Patent Office over the granting of a patent on a gene. Myriad also has patented the only test that measures the risk of breast and ovarian cancer.

Ms. Girard took a genetic test to see if her genes also put her at increased risk for ovarian cancer, which might require the removal of her ovaries. The test came back positive, so she wanted a second opinion from another test. But there can be no second opinion. A decision by the government more than 10 years ago allowed a single company, Myriad Genetics, to own the patent on two genes that are closely associated with increased risk for breast cancer and ovarian cancer, and on the testing that measures that risk.

On Tuesday, Ms. Girard, 39, who lives in the Austin, Tex., area, filed a lawsuit against Myriad and the Patent Office, challenging the decision to grant a patent on a gene to Myriad and companies like it. She was joined by four other cancer patients, by professional organizations of pathologists with more than 100,000 members and by several individual pathologists and genetic researchers.

The lawsuit, believed to be the first of its kind, was organized by the American Civil Liberties Union and filed in federal court in New York. It blends patent law, medical science, breast cancer activism and an unusual civil liberties argument in ways that could make it a landmark case.

Companies like Myriad, based in Salt Lake City, have argued that the patent system promotes innovation by giving companies the temporary monopoly that rewards their substantial investment in research and development.

Richard Marsh, Myriad’s general counsel, said company officials would not be able to comment on the lawsuit until they had fully reviewed the complaint.

The coalition of plaintiffs argues that gene patents actually restrict the practice of medicine and new research.

“With a sole provider, there’s mediocrity,” said Wendy K. Chung, the director of clinical genetics at Columbia University and a plaintiff in the case.

Dr. Chung and others involved with the suit do not accuse Myriad of being a poor steward of the information concerning the two genes at issue in the suit, known as BRCA1 and BRCA2, but they argue that BRCA testing would improve if market forces were allowed to work.

Harry Ostrer, director of the human genetics program at the New York University School of Medicine and a plaintiff in the case, said that many laboratories could perform the BRCA tests faster than Myriad, and for less money than the more than $3,000 the company charged.

Laboratories like his, he said, could focus on the mysteries still unsolved in gene variants. But if he tried to offer such services today, he said, he would be risking a patent infringement lawsuit from Myriad.

Christopher A. Hansen, senior national staff counsel for the civil liberties union, said the problem was with the patent office, not the company. He recalled that when he first heard that the office had granted a patent for a gene, “I said that can’t be true.”

As the A.C.L.U. explored the restrictions on competition that companies like Myriad had put in place — blocking alternatives to the patented tests, and even the practice of interpreting or comparing gene sequences that involved those genes — the restrictions started to look like not just a question of patent law, Mr. Hansen said, but of the First Amendment’s guarantee of free speech as well.

“What they have really patented,” he said, “is knowledge.”

A patent was also granted to a single company for genetic testing on long QT syndrome, which can lead to heart arrhythmias and sudden death, and to the HFE gene, linked to hereditary hemochromatosis, a condition in which iron accumulates in the blood and can cause organ damage. Doctors and scientists have complained about both patents.

On the other hand, the company that owns the patent to the gene CFTR, which has been linked to cystic fibrosis, has licensed the testing to dozens of laboratories, drawing praise from the medical world.

The decision to allow gene patents was controversial from the start; patents are normally not granted for products of nature or laws of nature. The companies successfully argued that they had done something that made the genes more than nature’s work: they had isolated and purified the DNA, and thus had patented something they had created — even though it corresponded to the sequence of an actual gene.

The argument may have convinced patent examiners, but it has long been a sore point for many scientists. “You can’t patent my DNA, any more than you can patent my right arm, or patent my blood,” said Jan A. Nowak, president of the Association for Molecular Pathology, a plaintiff in the case.

So far, however, two panels of government experts who have looked at the issue have not found significant impediments to research or medical care caused by gene patents. A 2006 report from the National Research Council found that patented biomedical research “rarely imposes a significant burden for biomedical researchers.”

That report and others, however, warn that the patent landscape “could become considerably more complex and burdensome over time.”

In the future, genetic tests are likely to involve the analysis of many genes at once, or even of a person’s full set of genes. Some 20 percent of the human genome is already included in patent claims, amounting to thousands of individual genes, says a draft report from the National Institutes of Health. The report warns that “it may be difficult for any one developer to obtain all the needed licenses” to develop the next generations of tests.

For Lisbeth Ceriani, a single mother from Newton, Mass., and a plaintiff in the case against Myriad, the biggest obstacle that gene patents present is one of cost. She has had breast cancer and a double mastectomy, but wants to have BRCA testing to determine her risk of ovarian cancer and help her decide whether to have her ovaries removed. But Myriad has refused to work with her insurance plan, Mass Health, and paying for the test herself is beyond her means.

She is reluctant to have surgery that might prove unnecessary, she said, but she also worries about her 8-year-old daughter and the inherited risk she might face. Which is why, Ms. Ceriani said, she wants to “find out if I have the mutation, so I can take the necessary steps to stay on the planet.”

“I want to be here,” she said, “to make sure she does her screening by the time she’s 30.”

Friday, January 9, 2009

Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.

Moral of the Story: Broccoli is just plain good for you. The first in the broccoli series, this article explains how broccoli consumption can distrupt oncogenic pathways in your prostate via genetic mechanisms. Basically, you eat broccoli, you have a certain gene, you dont get prostate cancer


Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.

Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, Chantry A, Jones AM, Ortori CA, Barrett DA, Ball RY, Mills RD, Mithen RF.
Phytochemicals and Health Programme, Institute of Food Research, Norwich Research Park, Norwich, United Kingdom.

BACKGROUND: Epidemiological studies suggest that people who consume more than one portion of cruciferous vegetables per week are at lower risk of both the incidence of prostate cancer and of developing aggressive prostate cancer but there is little understanding of the underlying mechanisms. In this study, we quantify and interpret changes in global gene expression patterns in the human prostate gland before, during and after a 12 month broccoli-rich diet.
METHODS AND FINDINGS: Volunteers were randomly assigned to either a broccoli-rich or a pea-rich diet. After six months there were no differences in gene expression between glutathione S-transferase mu 1 (GSTM1) positive and null individuals on the pea-rich diet but significant differences between GSTM1 genotypes on the broccoli-rich diet, associated with transforming growth factor beta 1 (TGFbeta1) and epidermal growth factor (EGF) signalling pathways. Comparison of biopsies obtained pre and post intervention revealed more changes in gene expression occurred in individuals on a broccoli-rich diet than in those on a pea-rich diet. While there were changes in androgen signalling, regardless of diet, men on the broccoli diet had additional changes to mRNA processing, and TGFbeta1, EGF and insulin signalling. We also provide evidence that sulforaphane (the isothiocyanate derived from 4-methylsuphinylbutyl glucosinolate that accumulates in broccoli) chemically interacts with TGFbeta1, EGF and insulin peptides to form thioureas, and enhances TGFbeta1/Smad-mediated transcription.
CONCLUSIONS: These findings suggest that consuming broccoli interacts with GSTM1 genotype to result in complex changes to signalling pathways associated with inflammation and carcinogenesis in the prostate. We propose that these changes may be mediated through the chemical interaction of isothiocyanates with signalling peptides in the plasma. This study provides, for the first time, experimental evidence obtained in humans to support observational studies that diets rich in cruciferous vegetables may reduce the risk of prostate cancer and other chronic disease.
TRIAL REGISTRATION: ClinicalTrials.gov NCT00535977.